These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 15254599)

  • 41. Duloxetine for the treatment of stress urinary incontinence in women: an integrated analysis of safety.
    Hurley DJ; Turner CL; Yalcin I; Viktrup L; Baygani SK
    Eur J Obstet Gynecol Reprod Biol; 2006 Mar; 125(1):120-8. PubMed ID: 16188367
    [TBL] [Abstract][Full Text] [Related]  

  • 42. An Open-Label Pilot Study of Duloxetine in Patients With Irritable Bowel Syndrome and Comorbid Major Depressive Disorder.
    Lewis-Fernández R; Lam P; Lucak S; Galfalvy H; Jackson E; Fried J; Rosario M; de la Cruz AA; Sánchez-Lacay A; Díaz S; Schneier F
    J Clin Psychopharmacol; 2016 Dec; 36(6):710-715. PubMed ID: 27755218
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Double-blind comparison of escitalopram and duloxetine in the acute treatment of major depressive disorder.
    Khan A; Bose A; Alexopoulos GS; Gommoll C; Li D; Gandhi C
    Clin Drug Investig; 2007; 27(7):481-92. PubMed ID: 17563128
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Mixed urinary incontinence symptoms: urodynamic findings, incontinence severity, and treatment response.
    Bump RC; Norton PA; Zinner NR; Yalcin I;
    Obstet Gynecol; 2003 Jul; 102(1):76-83. PubMed ID: 12850610
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Duloxetine in the treatment of stress urinary incontinence.
    Michel MC; Oelke M
    Womens Health (Lond); 2005 Nov; 1(3):345-58. PubMed ID: 19803876
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Changes in energy during treatment of depression: an analysis of duloxetine in double-blind placebo-controlled trials.
    Harada E; Kato M; Fujikoshi S; Wohlreich MM; Berggren L; Tokuoka H
    Int J Clin Pract; 2015 Oct; 69(10):1139-48. PubMed ID: 25980552
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Duloxetine versus escitalopram and placebo: an 8-month, double-blind trial in patients with major depressive disorder.
    Pigott TA; Prakash A; Arnold LM; Aaronson ST; Mallinckrodt CH; Wohlreich MM
    Curr Med Res Opin; 2007 Jun; 23(6):1303-18. PubMed ID: 17559729
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Bladder injury during sling operation in the treatment of SUI--review of literature and case report].
    Gałczyński K; Futyma K; Bar K; Rechberger T
    Ginekol Pol; 2012 Oct; 83(10):784-8. PubMed ID: 23383566
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Vortioxetine for depression in adults.
    Koesters M; Ostuzzi G; Guaiana G; Breilmann J; Barbui C
    Cochrane Database Syst Rev; 2017 Jul; 7(7):CD011520. PubMed ID: 28677828
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Efficacy, safety and tolerability of duloxetine 60 mg once daily in major depression.
    Cowen PJ; Ogilvie AD; Gama J
    Curr Med Res Opin; 2005 Mar; 21(3):345-56. PubMed ID: 15811202
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies.
    Tourian KA; Padmanabhan SK; Groark J; Brisard C; Farrington D
    Clin Ther; 2009 Jun; 31 Pt 1():1405-23. PubMed ID: 19698901
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Duloxetine in the treatment of depression: a double-blind placebo-controlled comparison with paroxetine.
    Goldstein DJ; Lu Y; Detke MJ; Wiltse C; Mallinckrodt C; Demitrack MA
    J Clin Psychopharmacol; 2004 Aug; 24(4):389-99. PubMed ID: 15232330
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Sexual function during long-term duloxetine treatment in patients with recurrent major depressive disorder.
    Montejo AL; Perahia DG; Spann ME; Wang F; Walker DJ; Yang CR; Detke MJ
    J Sex Med; 2011 Mar; 8(3):773-82. PubMed ID: 21091877
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Comparisons of the efficacy and safety of duloxetine for the treatment of fibromyalgia in patients with versus without major depressive disorder.
    Arnold LM; Hudson JI; Wang F; Wohlreich MM; Prakash A; Kajdasz DK; Chappell AS
    Clin J Pain; 2009; 25(6):461-8. PubMed ID: 19542792
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Symptoms following abrupt discontinuation of duloxetine treatment in patients with major depressive disorder.
    Perahia DG; Kajdasz DK; Desaiah D; Haddad PM
    J Affect Disord; 2005 Dec; 89(1-3):207-12. PubMed ID: 16266753
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Duloxetine for the treatment of major depressive disorder: safety and tolerability associated with dose escalation.
    Wohlreich MM; Mallinckrodt CH; Prakash A; Watkin JG; Carter WP
    Depress Anxiety; 2007; 24(1):41-52. PubMed ID: 16845641
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effects of the antidepressant duloxetine on body weight: analyses of 10 clinical studies.
    Wise TN; Perahia DG; Pangallo BA; Losin WG; Wiltse CG
    Prim Care Companion J Clin Psychiatry; 2006; 8(5):269-78. PubMed ID: 17235383
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Stress urinary incontinence in women: diagnosis and medical management.
    Deutchman M; Wulster-Radcliffe M
    MedGenMed; 2005 Dec; 7(4):62. PubMed ID: 16614684
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pharmacologic treatment of male stress urinary incontinence: systematic review of the literature and levels of evidence.
    Tsakiris P; de la Rosette JJ; Michel MC; Oelke M
    Eur Urol; 2008 Jan; 53(1):53-9. PubMed ID: 17920183
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Comparative Effect of Collaborative Care, Pain Medication, and Duloxetine in the Treatment of Major Depressive Disorder and Comorbid (Sub)Chronic Pain: Results of an Exploratory Randomized, Placebo-Controlled, Multicenter Trial (CC:PAINDIP).
    de Heer EW; Dekker J; Beekman ATF; van Marwijk HWJ; Holwerda TJ; Bet PM; Roth J; Timmerman L; van der Feltz-Cornelis CM
    Front Psychiatry; 2018; 9():118. PubMed ID: 29674981
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.